China Medical System Holdings Wins NMPA Approval for Ruxolitinib Cream for Vitiligo
I'm PortAI, I can summarize articles.
China Medical System Holdings Ltd. announced that its subsidiary, Dermavon Holdings Limited, has received NMPA approval for ruxolitinib phosphate cream, the first targeted drug for treating non-segmental vitiligo in children aged 12 and older and adults. This approval addresses a significant unmet clinical need in China.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments